Literature DB >> 17305887

Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?

H E Harris1, K P Eldridge, S Harbour, G Alexander, C-G Teo, M E Ramsay.   

Abstract

Whether differences in the natural history of hepatitis C virus (HCV) can be explained by differences in the infecting HCV type is unknown. The aim of this study was to investigate whether the HCV type might influence the clinical outcome of infection. Study serum samples were assembled from 749 individuals enrolled into the UK HCV National Register from which data on clinical outcomes were extracted. HCV-RNA-positive specimens were genotyped and HCV-RNA-negative specimens serotyped. Logistic regression analysis was used to investigate the independent effect of HCV type on viral clearance by comparing patients who were HCV RNA negative (n = 86) with those who were HCV RNA positive (n = 508). The same method was used to investigate whether HCV type was associated with histological stage of liver disease. The prevalence of HCV type 1 among those who cleared infection was 69% and among those who remained HCV RNA positive was 51%: Type 1 infections were more likely to be HCV RNA negative than non-1 types (OR 0.47, 95% CI 0.29-0.78, P = 0.003). Type 1 infections were also more likely to be associated with histological stage scores above the median when compared with non-1 types (OR 2.03, 95% CI 1.07-3.83, P = 0.03). In conclusion, HCV type 1 infection was more often HCV RNA negative, suggesting that spontaneous clearance may occur more commonly with this type. Among the RNA-positive infections, type 1 infection may be more aggressive than types 2/3.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305887     DOI: 10.1111/j.1365-2893.2006.00795.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  24 in total

Review 1.  Treatment of acute HCV infection.

Authors:  Jason Grebely; Gail V Matthews; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-22       Impact factor: 46.802

2.  Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study.

Authors:  Behzad Hajarizadeh; Bart Grady; Kimberly Page; Arthur Y Kim; Barbara H McGovern; Andrea L Cox; Thomas M Rice; Rachel Sacks-Davis; Julie Bruneau; Meghan Morris; Janaki Amin; Janke Schinkel; Tanya Applegate; Lisa Maher; Margaret Hellard; Andrew R Lloyd; Maria Prins; Ronald B Geskus; Gregory J Dore; Jason Grebely
Journal:  J Clin Virol       Date:  2014-09-08       Impact factor: 3.168

3.  The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection.

Authors:  Jason Grebely; Kimberly Page; Rachel Sacks-Davis; Maarten Schim van der Loeff; Thomas M Rice; Julie Bruneau; Meghan D Morris; Behzad Hajarizadeh; Janaki Amin; Andrea L Cox; Arthur Y Kim; Barbara H McGovern; Janke Schinkel; Jacob George; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Andrew R Lloyd; Margaret Hellard; Gregory J Dore; Maria Prins
Journal:  Hepatology       Date:  2013-11-22       Impact factor: 17.425

4.  Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.

Authors:  J S Doyle; K Deterding; J Grebely; H Wedemeyer; R Sacks-Davis; T Spelman; G Matthews; T M Rice; M D Morris; B H McGovern; A Y Kim; J Bruneau; A R Lloyd; K Page; M P Manns; M E Hellard; G J Dore
Journal:  J Viral Hepat       Date:  2015-06-22       Impact factor: 3.728

Review 5.  Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine.

Authors:  Jason Grebely; Maria Prins; Margaret Hellard; Andrea L Cox; William O Osburn; Georg Lauer; Kimberly Page; Andrew R Lloyd; Gregory J Dore
Journal:  Lancet Infect Dis       Date:  2012-05       Impact factor: 25.071

6.  Role of genetic polymorphisms in hepatitis C virus chronic infection.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Caterina Sagnelli; Lorenzo Onorato; Evangelista Sagnelli
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

Review 7.  The impact of ethnicity on hepatitis C virus treatment decisions and outcomes.

Authors:  Mauricio Lisker-Melman; José L Walewski
Journal:  Dig Dis Sci       Date:  2012-10-12       Impact factor: 3.199

8.  Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients.

Authors:  E Riva; F Maggi; F Abbruzzese; F Bellomi; G Giannelli; A Picardi; C Scagnolari; A Folgori; E Spada; E Piccolella; F Dianzani; G Antonelli
Journal:  Med Microbiol Immunol       Date:  2008-08-12       Impact factor: 3.402

Review 9.  Epidemiology and natural history of HCV infection.

Authors:  Behzad Hajarizadeh; Jason Grebely; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-02       Impact factor: 46.802

Review 10.  Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Mariantonietta Pisaturo; Nicola Coppola
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.